Choroidal Neovascularization Sales Market Outlook

The global choroidal neovascularization (CNV) market is projected to reach approximately USD 8.7 billion by 2035, registering a compound annual growth rate (CAGR) of around 6.1% from 2025 to 2035. The increasing prevalence of retinal diseases, especially age-related macular degeneration (AMD), is a significant growth factor contributing to this market expansion. In addition, advancements in treatment modalities, such as the introduction of innovative anti-VEGF therapies, have enhanced clinical outcomes and patient quality of life. The rising geriatric population, who are more prone to ocular disorders, also drives demand for CNV treatments. Furthermore, the increasing investments in research and development of novel therapeutic options are expected to bolster market growth during the forecast period.

Growth Factor of the Market

The choroidal neovascularization market is primarily propelled by the escalating incidence of eye-related disorders globally, particularly in aging populations. Anti-VEGF (vascular endothelial growth factor) therapies have revolutionized the treatment of CNV by significantly improving visual acuity and reducing the progression of associated diseases. Furthermore, technological advancements in ophthalmic surgical devices and therapeutic interventions have enhanced the efficiency and safety of procedures aimed at addressing CNV. The growing awareness regarding the importance of early diagnosis and treatment of ocular diseases among healthcare professionals and patients is also a notable driver. Additionally, collaborations between pharmaceutical companies and research institutions to develop more effective treatment options are expected to create a robust pipeline of products in the coming years.

Key Highlights of the Market

• The global CNV market is projected to achieve USD 8.7 billion by 2035.
• Anti-VEGF drugs are anticipated to dominate the product type segment due to their proven efficacy.
• North America holds the largest share of the market owing to advanced healthcare infrastructure.
• Growing prevalence of age-related macular degeneration is a key contributor to market growth.
• Technological advancements in treatment methods are expected to enhance patient outcomes.

By Product Type

Anti-VEGF Drugs:

Anti-VEGF drugs are the cornerstone of treatment for choroidal neovascularization, significantly improving patient outcomes through the inhibition of vascular endothelial growth factor. The increasing adoption of these therapies is due to their effectiveness in stabilizing vision and reducing the risk of severe visual loss, particularly in age-related macular degeneration. Major players like Regeneron Pharmaceuticals and Bayer have developed therapies such as Eylea and Lucentis, which dominate the market. This segment is expected to witness robust growth driven by ongoing clinical trials and the introduction of new formulations that enhance the therapeutic effect and minimize side effects.

Corticosteroids:

Corticosteroids are another vital treatment option for CNV, particularly in cases where anti-VEGF therapies are insufficient or contraindicated. These drugs work by reducing inflammation and controlling ocular pressure, thereby providing symptomatic relief and stabilizing vision. The market for corticosteroids is expanding due to increased awareness of their potential in treating various ocular diseases. However, the side effects associated with long-term use, such as increased intraocular pressure, remain a challenge. Innovations in drug delivery systems, such as sustained-release implants, are being explored to enhance the therapeutic index of corticosteroids.

Laser Therapies:

Laser therapies, particularly photocoagulation procedures, have been a long-standing treatment modality for choroidal neovascularization. Despite being overshadowed by anti-VEGF drugs, laser therapies continue to play a critical role in managing CNV, especially in specific patient populations. The precision and minimally invasive nature of laser treatments make them appealing, as they can be used for localized lesions with minimal collateral damage. The segment is anticipated to experience growth due to technological advancements and improved laser systems, which enhance treatment efficacy and safety.

Photodynamic Therapy:

Photodynamic therapy (PDT) utilizes light-activated drugs to selectively target and destroy abnormal blood vessels in the retina. This therapy is particularly beneficial for patients who may not respond well to anti-VEGF treatments. The unique mechanism of action of PDT allows it to be used in conjunction with other therapies, providing a multi-modal approach to treating CNV. The market for PDT is expected to grow as awareness increases regarding its advantages and as ongoing research yields new insights into its optimal use in clinical practice.

Surgical Devices:

Surgical devices used in the treatment of choroidal neovascularization encompass a range of tools and technologies employed in various surgical procedures. These devices, including vitrectomy instruments and specialized delivery systems, are critical in performing interventions like retinal surgeries and drug delivery. The segment is poised for growth owing to the increasing prevalence of retinal diseases and advancements in surgical methodologies that improve patient outcomes. As the demand for minimally invasive surgical techniques rises, manufacturers are focusing on innovation to produce more effective and user-friendly surgical devices.

By Application

Age-related Macular Degeneration:

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in individuals over the age of 50, making it a significant application area for treatments targeting choroidal neovascularization. The high prevalence of AMD worldwide has led to increased demand for effective therapies, particularly anti-VEGF drugs. As the global population continues to age, the incidence of AMD is expected to rise, further propelling the market. The ongoing research aimed at understanding the pathophysiology of AMD is likely to yield new therapeutic targets, enhancing treatment options for affected patients.

Pathological Myopia:

Pathological myopia is a severe form of refractive error characterized by excessive elongation of the eyeball, leading to various ocular complications, including CNV. As the prevalence of myopia increases globally, particularly among younger populations, the demand for interventions addressing the associated complications also rises. The market for CNV treatments related to pathological myopia is expected to expand, driven by the growing awareness of the condition and the need for effective management strategies. Ongoing clinical studies focusing on the efficacy of existing treatments in myopic patients are likely to contribute to market growth.

Angioid Streaks:

Angioid streaks are associated with various systemic diseases and can lead to CNV, presenting a unique challenge in treatment. Their occurrence in patients with conditions such as pseudoxanthoma elasticum highlights the need for tailored therapeutic strategies. The demand for treatments focused on angioid streaks has been growing as research continues to elucidate the underlying mechanisms and optimal intervention strategies. Market growth in this application area is anticipated as healthcare providers seek effective treatment options for these complex cases.

Central Serous Chorioretinopathy:

Central serous chorioretinopathy (CSCR) is characterized by fluid accumulation under the retina, leading to visual distortion and impairment. While not all cases progress to CNV, the potential for this complication necessitates effective treatment options. The growing recognition of CSCR as a significant contributor to visual impairment has led to increased research and development efforts aimed at addressing this condition. As healthcare providers focus on early intervention and management strategies, the application segment related to CSCR treatments is projected to grow concurrently with the broader CNV market.

Others:

This segment encompasses various other conditions that can lead to choroidal neovascularization, including inherited retinal diseases and secondary CNV associated with trauma. The diversity of this category reflects the multifactorial nature of CNV and the need for comprehensive treatment approaches. As research continues to explore the relationship between these conditions and CNV, the demand for targeted therapies is expected to increase. Market growth in this segment will be driven by advances in genetic research and the development of personalized treatment regimens for affected patients.

By Distribution Channel

Hospitals:

Hospitals play a critical role in the distribution of CNV treatments, as they are often the primary care setting for patients requiring advanced ocular therapies. The integration of ophthalmology departments within hospitals facilitates access to a wide range of treatment modalities, including surgical and pharmacological options. The market share attributed to hospitals is expected to grow due to rising patient volumes, the establishment of specialized eye care centers, and advancements in hospital infrastructure that enhance patient management and treatment delivery.

Ophthalmic Clinics:

Ophthalmic clinics specialize in diagnosing and treating eye-related conditions, making them a vital distribution channel for choroidal neovascularization therapies. The personalized care and expertise provided by these clinics are integral to improving patient outcomes. As awareness of the importance of eye health increases, more individuals are seeking care from specialized clinics, contributing to market growth. Moreover, the adoption of telemedicine practices in ophthalmology has expanded patient reach, allowing clinics to serve a more extensive patient population.

Retail Pharmacies:

Retail pharmacies form a vital link in the distribution chain of CNV treatments, particularly for patients requiring ongoing medication management. These pharmacies provide convenient access to prescription and over-the-counter medications, making them an essential resource for patients. The expansion of retail pharmacy services, including the provision of health consultations and medication therapy management, is expected to enhance patient adherence to prescribed therapies. As retail pharmacies increasingly participate in patient education and awareness initiatives, their role in the CNV market is set to expand.

Online Pharmacies:

The rise of online pharmacies has transformed the way patients access medications for choroidal neovascularization. With the convenience and ease of purchasing medications online, patients can obtain their prescriptions without the need to visit a physical location. This channel is particularly appealing to those who may have mobility challenges or who prefer the discretion of online transactions. The growth of this segment is driven by the increasing acceptance of online healthcare services, coupled with the ongoing digitalization of the healthcare sector. Regulatory developments that support online pharmaceutical sales are also anticipated to promote this distribution channel further.

By Region

The choroidal neovascularization market is geographically diverse, with North America leading in market share, followed by Europe and Asia Pacific. In North America, the market is projected to grow significantly, driven by advanced healthcare infrastructure, high levels of healthcare expenditure, and the presence of leading pharmaceutical companies. The region holds a market share of approximately 40% and is expected to maintain a CAGR of around 6.5% through 2035. In Europe, the market is also robust, supported by a large geriatric population and increasing awareness about eye health, contributing to a steady growth trajectory.

Asia Pacific is emerging as a significant player in the CNV market due to the increasing incidence of retinal diseases and the expansion of healthcare access in developing nations. The region is anticipated to witness the highest CAGR of approximately 7.0% during the forecast period as countries enhance their healthcare systems and invest in ophthalmic care. Latin America and the Middle East & Africa are also witnessing gradual growth, albeit at a slower pace, owing to the developing healthcare infrastructure and varying levels of access to advanced treatments.

Opportunities

The choroidal neovascularization market presents numerous opportunities for growth, particularly through technological advancements and innovations in treatment approaches. Pharmaceutical companies are investing heavily in research and development to create new anti-VEGF formulations and combination therapies that enhance efficacy and ensure better patient compliance. Additionally, the emergence of gene therapy and other novel modalities holds significant promise for treating CNV more effectively. As these products progress through clinical trials and regulatory approvals, they are likely to capture substantial market share, benefiting both manufacturers and patients alike.

Furthermore, increasing awareness and education regarding ocular health among the general population is creating opportunities for market expansion. Healthcare providers are emphasizing the importance of regular eye check-ups, especially in at-risk populations such as the elderly. This focus on early detection and intervention encourages patient engagement and adherence to treatment protocols, thereby driving demand for CNV therapies. Additionally, collaborations between stakeholders, including healthcare institutions, pharmaceutical companies, and patient advocacy groups, are pivotal in improving access to treatments and fostering innovation, creating a conducive environment for market growth.

Threats

Despite the promising growth of the choroidal neovascularization market, several threats could hinder its progress. One significant concern is the high cost associated with advanced therapies, such as anti-VEGF drugs, which may limit access for patients in lower-income regions or those without adequate insurance coverage. The economic burden of these treatments can lead to discrepancies in healthcare access, ultimately impacting patient outcomes and market penetration. Additionally, the presence of alternative treatment options and the emergence of competitive therapies may threaten the market share of established products, necessitating ongoing innovation and strategic positioning by companies.

Furthermore, regulatory challenges and lengthy approval processes can delay the introduction of new therapies and limit market potential. Compliance with stringent regulations governing drug safety, efficacy, and marketing can be resource-intensive for companies. Additionally, fluctuations in government healthcare policies and reimbursement structures may also impact market dynamics and profitability for pharmaceutical manufacturers. Thus, companies must remain agile and responsive to the regulatory landscape to mitigate these threats effectively.

Competitor Outlook

• Regeneron Pharmaceuticals
• Bayer AG
• Novartis AG
• Roche Holdings AG
• Allergan, Inc.
• Horizon Therapeutics plc
• Genentech, Inc.
• Alimera Sciences, Inc.
• IRIDEX Corporation
• Amgen Inc.
• kphasics, Inc.
• Ophthotech Corporation
• Opthea Limited
• Neurotech Pharmaceuticals, Inc.
• EyePoint Pharmaceuticals, Inc.

The competitive landscape of the choroidal neovascularization market is marked by the presence of several prominent players, each striving to establish a strong foothold in this growing field. Major companies are focusing on innovative research and development, exploring new therapeutic targets, and engaging in strategic partnerships to enhance their product offerings. The rivalry among these players is intensifying as they seek to capture market share through the introduction of novel therapies and technologies. Companies that successfully navigate regulatory hurdles and demonstrate compelling clinical data are likely to gain a competitive edge in the market.

Among the leading companies, Regeneron Pharmaceuticals and Bayer AG stand out with their flagship product Eylea, which has set the standard for anti-VEGF therapy in treating CNV. Their continued investment in clinical trials and exploration of combination therapies demonstrates a commitment to maintaining their competitive advantage. Novartis AG and Roche Holdings AG also have a significant presence in the market, with established products for treating various retinal diseases, including CNV. These companies are leveraging their robust pipelines and extensive distribution networks to ensure widespread access to their therapies.

In addition to established players, emerging biotechnology firms are entering the market with innovative treatment solutions, particularly in gene therapy and novel delivery systems. These companies often focus on niche applications within the CNV space, capitalizing on unmet medical needs and providing alternative treatment options. As the market evolves, the introduction of biosimilars may also reshape the competitive landscape, offering cost-effective alternatives to existing therapies. Overall, the choroidal neovascularization market is characterized by dynamic competition and continual innovation, ensuring that companies remain agile in response to evolving patient needs and market trends.